Program
Nivolumab
Also written as “nivolumab”, “ONO-4538” and “BMS-936558 (MDX-1106)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Renal Cell · Carcinoma, Hepatocellular · Colorectal Neoplasms, led by 8 companies.
Drug pageNivolumab: every studyMany companies study it; this page follows only the 145 they lead. All 1,032 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 12410 open or running | phase 4since Nov 2, 2015 | Feb 27, 2007 | Feb 5, 2027phase 2 · NCT06946797 |
| Ono Pharmaceutical | 144 open or running | phase 3since Oct 9, 2014 | Jan 26, 2009 | Dec 31, 2027phase 2 · NCT04566380 |
| Pfizerits history only | 20 open or running | phase 2since Oct 7, 2015 | Oct 7, 2015 | none ahead |
| Ella Therapeuticsits history only | 10 open or running | phase 2since Aug 13, 2020 | Aug 13, 2020 | none ahead |
| ExcellaBioits history only | 10 open or running | phase 2since Oct 20, 2017 | Oct 20, 2017 | none ahead |
| Nilogen Oncosystemsits history only | 10 open or running | early phase 1since Dec 3, 2017 | Dec 3, 2017 | none ahead |
| Rampart Healthits history only | 10 open or running | phase 2since Aug 9, 2019 | Aug 9, 2019 | none ahead |
| USWM CTits history only | 10 open or running | phase 2since Oct 26, 2022 | Oct 26, 2022 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Halozyme Therapeutics, Medarex, Parexel, Astellas Pharma, Akamis Bio, Hoffmann-La Roche, Nektar Therapeutics, Eli Lilly, AbbVie and PPD DEVELOPMENT, LP.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Ono Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 26, 2009First study: phase 1 study in Malignant Solid TumorFirst studyNCT00836888 · 17 enrolled · Japan
- Jun 18, 2014Phase 2 study in Advanced Non-small Cell Lung Cancer (NSCLC)NCT02175017 · 104 enrolled · Korea, Republic of
- Sep 30, 20142 phase 1 studies in Advanced Solid TumorsNCT02261298, NCT02261285
- Oct 9, 2014Phase 3 study in Stomach NeoplasmsNCT02267343 · 493 enrolled · Japan, Korea, Republic of, Taiwan
- Sep 30, 2015Phase 3 study in Esophageal NeoplasmsNCT02569242 · 419 enrolled · United States, Denmark, Germany and more
- Oct 20, 2015Phase 2 study in Advanced Non-small Cell Lung CancerNCT02582125 · 53 enrolled · Taiwan
- Mar 29, 2016Phase 3 study in Stomach NeoplasmsNCT02746796 · 680 enrolled · Japan, Korea, Republic of, Taiwan
- Dec 27, 2016Phase 3 study in Stomach NeoplasmsNCT03006705 · 800 enrolled · China, Japan, Korea, Republic of and more
- Apr 12, 2017Phase 3 study in Carcinoma, Non-Small-Cell LungNCT03117049 · 550 enrolled · Japan, Korea, Republic of, Taiwan
- Sep 22, 2020Phase 2 study in Pan-tumorNCT04566380 · 70 planned · Japan, South Korea, Taiwan
- Oct 6, 2021Phase 3 study in Stomach NeoplasmsNCT05144854 · 626 enrolled · Japan, South Korea, Taiwan
- Sep 30, 2024Phase 2 study in Rhabdoid TumorNCT06622941 · 23 planned · Japan
- Apr 13, 2025Phase 2 study in Richter's TransformationNCT06936943 · 14 planned · Japan
- Oct 14, 2026Primary completion moved from 2026-12-31 to 2027-12-31Date moved laterphase 2 · +12 months · NCT04566380
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Pan-tumorNCT04566380
- Jan 31, 2029Primary completion: phase 2 study in Rhabdoid TumorNCT06622941
- Jul 31, 2029Primary completion: phase 2 study in Richter's TransformationNCT06936943
TargetBeta
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 14 Ono Pharmaceutical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06936943Richter's Transformation · Japan | 2 | Recruiting | Jul 31, 2029 | 14 |
| NCT06622941Rhabdoid Tumor · Japan | 2 | Recruiting | Jan 31, 2029 | 23 |
| NCT05144854Stomach Neoplasms · Japan, South Korea, Taiwan | 3 | Active, not recruiting | Oct 20, 2025 | 626 |
| NCT04566380Pan-tumor · Japan, South Korea, Taiwan | 2 | Recruiting | Dec 31, 2027 | 70 |
| NCT03117049Carcinoma, Non-Small-Cell Lung · Japan, Korea, Republic of, Taiwan | 3 | Completed | Feb 10, 2020 | 550 |
| NCT03006705Stomach Neoplasms · China, Japan, Korea, Republic of and more | 3 | Completed | Aug 17, 2022 | 800 |
| NCT02746796Stomach Neoplasms · Japan, Korea, Republic of, Taiwan | 3 | Completed | Jan 2020 | 680 |
| NCT02582125Advanced Non-small Cell Lung Cancer · Taiwan | 2 | Completed | Jan 4, 2021 | 53 |
| NCT02569242Esophageal Neoplasms · United States, Denmark, Germany and more | 3 | Completed | Oct 23, 2020 | 419 |
| NCT02267343Stomach Neoplasms · Japan, Korea, Republic of, Taiwan | 3 | Completed | Aug 2016 | 493 |
| NCT02261298Advanced Solid Tumors · Korea, Republic of | 1 | Completed | Jun 2015 | 18 |
| NCT02261285Advanced Solid Tumors · Korea, Republic of | 1 | Completed | Dec 2014 | 18 |
| NCT02175017Advanced Non-small Cell Lung Cancer (NSCLC) · Korea, Republic of | 2 | Completed | Nov 2015 | 104 |
| NCT00836888Malignant Solid Tumor · Japan | 1 | Completed | Sep 2010 | 17 |
How it is read
Names in the registry
- “Nivolumab”, 115 entries
- “nivolumab”, 18 entries
- “ONO-4538”, 13 entries
- “BMS-936558 (MDX-1106)”, 5 entries
- “Nivolumab + Relatlimab”, 3 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 36 studies
- Melanoma, 21 studies
- Carcinoma, Renal Cell, 11 studies
- Carcinoma, Hepatocellular, 6 studies
- Colorectal Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.